Literature DB >> 33030468

A concise route to MK-4482 (EIDD-2801) from cytidine.

N Vasudevan1, Grace P Ahlqvist, Catherine P McGeough, Dinesh J Paymode, Flavio S P Cardoso, Tobias Lucas, Jule-Phillip Dietz, Till Opatz, Timothy F Jamison, Frank B Gupton, David R Snead.   

Abstract

A two-step route to MK-4482 (EIDD-2801, 1) was developed consisting of an esterification and hydroxamination of cytidine. The selective acylation and direct amination eliminate the need for protecting and activating groups and proceed in overall yield of 75%, a significant advancement over the reported yield of 17%. The step count is reduced from five transformations to two, and expensive uridine is replaced with the more available cytidine.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33030468     DOI: 10.1039/d0cc05944g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  12 in total

1.  Conversion of N-acyl amidines to amidoximes: a convenient synthetic approach to molnupiravir (EIDD-2801) from ribose.

Authors:  Ajaz Ahmed; Qazi Naveed Ahmed; Debaraj Mukherjee
Journal:  RSC Adv       Date:  2021-11-10       Impact factor: 4.036

2.  A High-Yielding Synthesis of EIDD-2801 from Uridine.

Authors:  Alexander Steiner; Desiree Znidar; Sándor B Ötvös; David R Snead; Doris Dallinger; C Oliver Kappe
Journal:  European J Org Chem       Date:  2020-11-12

3.  Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.

Authors:  Grace P Ahlqvist; Catherine P McGeough; Chris Senanayake; Joseph D Armstrong; Ajay Yadaw; Sarabindu Roy; Saeed Ahmad; David R Snead; Timothy F Jamison
Journal:  ACS Omega       Date:  2021-04-08

Review 4.  Review on molnupiravir as a promising oral drug for the treatment of COVID-19.

Authors:  Elham Zarenezhad; Mahrokh Marzi
Journal:  Med Chem Res       Date:  2022-01-03       Impact factor: 2.351

5.  Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19.

Authors:  John A McIntosh; Tamas Benkovics; Steven M Silverman; Mark A Huffman; Jongrock Kong; Peter E Maligres; Tetsuji Itoh; Hao Yang; Deeptak Verma; Weilan Pan; Hsing-I Ho; Jonathan Vroom; Anders M Knight; Jessica A Hurtak; Artis Klapars; Anna Fryszkowska; William J Morris; Neil A Strotman; Grant S Murphy; Kevin M Maloney; Patrick S Fier
Journal:  ACS Cent Sci       Date:  2021-10-29       Impact factor: 14.553

Review 6.  Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19.

Authors:  Patrick S Fier; Yingju Xu; Marc Poirier; Gilmar Brito; Michelle Zheng; Rachel Bade; Eric Sirota; Kevin Stone; Lushi Tan; Guy R Humphrey; Darryl Chang; Jameson Bothe; Yongqian Zhang; Frank Bernardoni; Steve Castro; Michael A Zompa; Jerry Taylor; Kevin M Sirk; Anthony Diaz-Santana; Ike Diribe; Khateeta M Emerson; Bharath Krishnamurthi; Ralph Zhao; Michael Ward; Chengqian Xiao; Honggui Ouyand; Jianfeng Zhan; William J Morris
Journal:  Org Process Res Dev       Date:  2021-12-10       Impact factor: 3.317

7.  An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir.

Authors:  Ashleigh J Burke; William R Birmingham; Ying Zhuo; Thomas W Thorpe; Bruna Zucoloto da Costa; Rebecca Crawshaw; Ian Rowles; James D Finnigan; Carl Young; Gregory M Holgate; Mark P Muldowney; Simon J Charnock; Sarah L Lovelock; Nicholas J Turner; Anthony P Green
Journal:  J Am Chem Soc       Date:  2022-02-28       Impact factor: 15.419

8.  Cost of Goods Analysis Facilitates an Integrated Approach to Identifying Alternative Synthesis Methodologies for Lower Cost Manufacturing of the COVID-19 Antiviral Molnupiravir.

Authors:  Christopher Peterson; Sayan Paria; Anita Deshpande; Saeed Ahmad; Andrew Harmon; John Dillon; Trevor Laird
Journal:  Gates Open Res       Date:  2022-02-16

Review 9.  Molnupiravir and Its Antiviral Activity Against COVID-19.

Authors:  Lili Tian; Zehan Pang; Maochen Li; Fuxing Lou; Xiaoping An; Shaozhou Zhu; Lihua Song; Yigang Tong; Huahao Fan; Junfen Fan
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 7.561

Review 10.  Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis.

Authors:  Vijayagopal Gopalsamuthiram; Appasaheb L Kadam; Jeffrey K Noble; David R Snead; Corshai Williams; Timothy F Jamison; Chris Senanayake; Ajay K Yadaw; Sarabindu Roy; Gopal Sirasani; B Frank Gupton; Justina Burns; Daniel W Cook; Rodger W Stringham; Saeed Ahmad; Rudy Krack
Journal:  Org Process Res Dev       Date:  2021-12-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.